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Recent phytochemical analysis of Toussaintia orientalis leaves yielded series of novel bioactive N-
cinnamoyltetraketide derivatives namely toussaintines A-G (t_1 - t_8) some portraying cytotoxicity 
against the triple negative aggressive human breast cancer cell line (MDA-MB-231) among other 
potencies. Despite having broad bioactivity spectrum, their general drug-likeness profiles and 
mode of action (simulated or actual) targeting any enzyme remains uninvestigated. In silico 
pharmacokinetic, drug-likeness descriptors and molecular docking of the compounds t_1-t_8 
targeting inhibition of cyclooxygenase-2 (COX-2) enzyme were evaluated. The Lipinski Rule of 
Five heralded the pharmacokinetic properties of the studied metabolites. The studied compounds 
were docked with COX-2 following already established protocol. ADMET descriptors fell within 
the recommended range, except for compound t_3 that was predicted to potentially have positive 
blood brain barrier (BBB+) penetration. Docking studies indicated N-cinnamoyltetraketide 
derivatives as potential inhibitors of COX-2 enzyme.  Compounds t_3 and t_5 showed lower 
binding energy of -13 and -12.3 kcal/mol, respectively, being closely comparable to celecoxib (-
12.3 kcal/mol) indicating compatibility with the protein receptor. The findings provide baseline 
information on drug or lead-likeness and potential mode of action of the studied molecules 
towards inhibition of COX-2 enzyme. 
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INTRODUCTION 
Drug discovery and development are time 
consuming and expensive multistep 
processes. A number of drug candidates 
usually face limitations to enter into clinical 
trials and pharmaceutical markets (Darvas et 
al. 2002), whereas the few that enter into the 
market are often banned or stopped shortly 
after commencement of their clinical use. 
Poor pharmacokinetics and toxicity of the 
efficaciously promising drug candidates are 
the main obstacles among other factors for 
development of drug into clinical 
applications (Waterbeemd and Gifford 2003; 
Boobis et al. 2002). For economic reasons 
therefore, poor drug-like candidates need to 
be eliminated earlier during drug 
development (Boobis et al. 2002). Today, 
the use of computational approach in drug 
discovery and development provides a safer 
and the fastest means of reducing cost 
related to experimental studies (Boobis et al. 
2002, Ntie-Kang 2013). Thus, in silico 
approach is preliminarily used in drug 
discovery to evaluate drug-likeness 
properties such as absorption, distribution, 
metabolism, elimination and toxicity 
(ADMET) of compounds at early stages of 




their development (Boobis et al. 2002). Such 
evaluation facilitate selection of compounds 
with high probability of becoming lead 
molecules or drugs while eliminating those 
with less probabilities (Boobis et al. 2002, 
Lagorce et al. 2008). 
 
Recently, phytochemical analysis of 
Toussaintia orientalis Verdc (Annonaceae), 
a medicinal plant endemic to Tanzania 
yielded N-cinnamoyltetraketide derivatives 
namely toussaintines A-G (t_1 - t_8, 
respectively, Figure 1) (Samwel et al. 2011, 
Nyandoro et al. 2015) some having 
cytotoxic properties against the triple 
negative aggressive human breast cancer cell 
line (MDA-MB-231) (Nyandoro et al. 
2015). The compounds are also reported to 
possess antitubecular activities against 
Mycobacterium tuberculosis (H37Rv strain) 
(Nyandoro et al. 2015), antiviral efficacy 
against Infectious Bursal Disease and 
Newcastle Disease Viruses (Nyandoro et al. 
2014) and other antimicrobial activities 
(Samwel et al. 2011). Different extract 
preparations from T. orientalis are used in 
traditional medicine for remedy of 
respiratory infections and inflammation 
associated with irritating skin rashes 
(Samwel et al. 2011). Despite the reported 
bioactivities of the N-cinnamoyltetraketide 
derivatives, their general drug-likeness 
profiles and mode of action (simulated or 
actual) targeting any enzyme remains 
uninvestigated. In the present study, in silico 
pharmacokinetic drug-likeness properties of 
these bioactive metabolites (t_1 - t_8) 
prefigured by Lipinski Rule of Five 
followed by molecular docking targeting 
inhibition of cyclooxygenase-2 (COX-2) 
enzyme were evaluated. 
 
Cyclooxygenase (COX) enzymes exist in 
two isoforms, cyclooxygenase 1 (COX-1) 
and cyclooxygenase 2 COX-2). The two 
isoenzymes convert arachidonic acid to 
prostaglandin, resulting in pain and 
inflammation (Madeswaran et al. 2012). 
They exert metabolism roles in different 
physiological situations and disease 
processes ranging from inflammatory, 
pyretic, thrombotic, neurodegenerative to 
oncological illnesses. COX-1 is known to be 
present in most tissues including the 
gastrointestinal tract where it maintains the 
normal lining of the stomach. It is also 
involved in kidney and platelet function. On 
the other hand, COX-2 is primarily present 
at the sites of inflammation (Madeswaran et 
al. 2012) and positively linked to 
proliferation of cancerous cells including 
human breast cancer cells (Ranger et al. 
2004). Thus, due to COX enzymes other 
functions, preferential inhibition of COX-2 
over COX-1 is considered desirable. A 
number of cinnamic acid derivatives have 
been reported to possess interesting 
antioxidant, anti-inflammatory, cytotoxic, 
lipoxygenase inhibition properties (Pontiki 
et al. 2014). Consequently, N-
cinnamoyltetraketide derivatives having 
demonstrated cytotoxicity against the human 
breast cancer cells (Nyandoro et al. 2015), 
are hereby investigated in silico to reveal 
whether COX-2 enzyme could be their 
molecular targets as they exert their 
cytotoxic action. 
 
MATERIALS AND METHODS 
Sources of data and chemical structure  
Information regarding structure and 
bioactivities of N-cinnamoyltetraketide 
derivatives were obtained from the 
previously published work (Samwel et al. 
2011, Nyandoro et al. 2015) and the 
compounds are herein referred to as t_1 - 
t_8. The structures were initially drawn in 
ChemDraw Pro Software 12.0 and served as 
.sdf and .mol file format.  
 
ADMET descriptor calculations  
ADMET related descriptors were calculated 
by using MedChem Designer, ACD/iLab ver 
2.0 and Pre ADMET online server. The 
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software generated descriptors used in 
ADME prediction. Pharmacokinetic profiles 
of the N-cinnamoyltetraketide derivatives 
were assessed by using the ADMET drug-
likeness parameters. The calculated 
descriptors for drug-likeness based on the 
Lipinski’s Rule of Five (Lipinski et al. 1997) 
included molecular weight (MW), hydrogen 
bond donor (HBD), hydrogen bond acceptor 
(HBA), lipophilicity (logP) and topological 
polar surface area (TPSA). The other 
parameter calculated was the number of 
rotatable bonds (nRB). Other predicted 
properties based on the method described by 
Jorgensen and Duffy (2002) includes 
logarithm of binding constant to human 
serum albumin (log KHSA) range of -1.5 to 
1.2 (Colmenarejo et al. 2001), logarithm of 
blood/brain barrier (BBB) partition 
coefficient (log B/B) range of -3 to 1 (Luco 
1999) and apparent Caco-2 cell membrane 
permeability (caco-2 permeability), 
(Stenberg et al. 2001). Other descriptors 
were: apparent Madin-Darby canine kidney 
(MDCK) cell permeability in nm s
-1
range 
<25 poor, and >500 great (Irvine et al. 
1999), IC50 value for blockage of hERG 
K
+
























































Figure 1: N-cinnamoyltetraketide derivatives: Toussaintine A – G (t_1 – t_8) (Samwel et al. 2011; 
Nyandoro et al. 2015) 
 
Molecular docking studies 
Protein and ligands preparation  
The three dimension structure (3D) of target 
COX-2 enzyme was retrieved from RCSB 
protein data bank (PDB ID: 3NTG) with 
2.19 Å resolution (Wang et al. 2010). Hetero 
atoms and water were removed from the 
protein binding sites. Protein structure was 
prepared using Chimera software 
(http://www.cgl.ucsf.edu/chimera). 
Furthermore, the protein was checked for 
allowed and disallowed regions using the 
Ramachadran plot and the ProSA was used 
to display the Z-score energetic plots. 
Molecular framework of the cytotoxic N-
cynnamoyltetraketide derivatives, herein, 




now referred to as ligands (t_1, t_2, t_3, t_4, 
t_5, t_6, t_7 and t_8) originated from the 
literature (Samwel et al. 2011, Nyandoro et 
al. 2015). Their structures were drawn in 
ChemDraw Pro 12.0 software and exported 
as .mol and .pdb file. Hydrogen was added 
and structures were energy minimized. 
 
Molecular docking  
Docking experiments were done following 
established procedure (Muhammad and 
Fatima 2015, Shadrack et al. 2016) using 
PyRx virtual screening tool, with AutoDock 
Vina docking option based on scoring 
functions. The energy interaction of 3NTG 
with ligands was assigned as grind point. 
The parameters were set as default, except 
for energy of interaction of ligands and 
3NTG which was evaluated using atomic 
affinity potentials computed on a grid. 
Docking of the ligands was validated using 
celecoxib drug. PyMol or Malegro 
Molecular Viewer software was used to 
analyze the binding sites and orientations of 
ligands and COX-2 enzyme. 
 
RESULTS AND DISCUSSION  
 
The Lipinski Rule of Five Evaluation of 
Drug-likeness  
The Lipinski’s Rule of Five including its 
extended metrics (Lipinski et al. 1997, 
Lipinski 2000) was used to predict the drug-
likeness of the natural products under 
investigations prior to further ADMET and 
other pertinent pharmacokinetic descriptors 
assessment. The parameters used to assess 
drug-likeness of the studied compounds 
includes molecular weight (MW), number of 
hydrogen bond acceptors (HBA), number of 
hydrogen bond donor (HBD), octanol-water 
partition coefficient (lipophilicity, log P), 
the topological polar surface area (TPSA) 
and the number of rotatable bonds (RB). 
Compound which obey the Lipinski Rule of 
Five should have MW < 500 Da, TPSA ≤ 
140 Å
2
, HBA < 10, HBD <5, log P < 5 and 
RB < 10. All N-cinnamoyltetraketide 
derivatives investigated were in agreement 
with the rule (Table 1). The MW analysis of 
the compounds showed the highest mass of 
361.397 Da for t_6 and t_7 (Table 1). Thus, 
the molecular weights were in agreement 
with the Lipinski Rule of Five for small 
molecules. The number of HBA (which 
includes number oxygen and nitrogen) and 
HBD calculated were found to be <7 and <2, 
respectively for all compounds, being in 
compliance with the rule. All N-
cinnamoyltetraketide derivatives showed log 
P <5 and TPSA greater than 60, but less 
than 100 qualifying the rule requirement for 
these criteria. The log P < 5 indicates good 
permeability across cell membrane in human 
body as well as low toxicity. According to 
the rule, the molecules having a TPSA value 
>140 Å
2 
have a minimal chance to permeate 
the cell membrane. The computed number of 
rotatable bonds was found to be ≤ 7 for all 
compounds, being in agreement with the 
rule as for other analyzed descriptors. 
 
Pharmacokinetics Predictions 
Blood-brain barrier (BBB) penetration 
prediction  
Drugs which are too polar and those with 
high TPSA value (60-90 Å
2
) have poor or no 
BBB permeation. BBB permeability is 
measured by two parameters, log B/B 
(concentration of drug in blood/brain) and 
log PS (permeability surface area product) 
(Suenderhauf et al. 2012, Carpenter et al. 
2014). The predicated log B/B penetration 
(Table 2) was used further to predict 
whether compounds can access the central 
nervous system (CNS). The predicated CNS 
activity (+) and CNS inactivity (-) were 
computed in a +1(activity) to -1 (inactivity) 
scale. None of the N-cinnamoyltetraketide 
derivatives showed activity to the CNS 
(Table 2). The computed log B/B fell within 
the recommended range for blood brain 
barrier predication (-3 to 1) (Carpenter et al. 
2014). However, unlike other N-
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cinnamoyltetraketide derivatives, t_3 was 
indicated to be BBB positive based on 
support vector machine (SVM) prediction 
(Table 2), the outcome that correlates to its 
low TPSA value (57.61 Å
2
) and MW 
(283.329 Da). The predicated TPSA values 
were ≥ 60 Å
2
 for all N-cinnamoyltetraketide 
derivatives, except for t_3 whose TPSA 
value was slightly < 60 Å
2
 and 
correspondingly the lowest MWt. Generally, 
compounds with TPSA < 60-70 Å
2 
have 
higher chances for BBB permeation 
(Jouyban and Soltani, 2012). 
 
Table 1: Physicochemical descriptors of compounds t_1 – t_8 
 
Name MlogP S+logP S+logD RuleOf5 aMWt bHBA cTPSA dHBD enRB 
t_1 1.094 0.903 0.903 0 297.313 5 74.68 1 2 
t_2 1.171 0.785 0.785 0 299.328 5 77.84 2 3 
t_3 1.553 1.107 1.107 0 283.329 4 57.61 1 2 
t_4 1.171 0.932 0.931 0 299.328 5 75.63 2 3 
t_5 0.559 0.917 0.916 0 329.355 6 92.7 2 6 
t_6 0.559 0.917 0.916 0 329.355 6 92.7 2 6 
t_7 0.11 0.786 0.785 0 361.397 7 101.93 2 7 




Molecular weight (MWt), 
b
number of hydrogen bond acceptor (HBA), 
c
topological polar surface 
area (TPSA) 
d
number of hydrogen bond donor (HBD), 
e
number of rotatable bonds. 
 
Table 2: Blood-Brain Barrier Permeability Properties of the compounds t_1 - t_8  
 
Compounds  log BB clog PS dlog (PS*fu, brain) 
b
BBB+/- aCNS+/- 
t_1 -0.74 -2.1 -2.4 - - 
t-2  -0.63 -2.0 -2.4 - - 
t_3 -0.53 -1.7 -2.2 + - 
t_4 -0.5 -2.1 -2.5 - - 
t_5 -0.5 -2.2 -2.6 - - 
t_6 -0.49 -2.2 -2.6 - - 
t_7 -0.22 -2.4 -2.7 - - 
t_8 -0.22 -2.4 -2.7 - - 
a
Central Nervous System active(+) and inactive(-), 
b
Predicated on support vector machine (SVM) 
with pubchem fingerprint, 
c




Predication of the plasma protein binding 
(PPB) 
Drugs bind reversibly to human plasma 
protein with varying degree of association.  
 
The binding affects the pharmacokinetic 
properties in terms of volume of distribution, 
metabolism and clearance as well as the 
pharmacological effects of the drugs 
(Ghafourian and Amin 2013). Drugs with 
high protein binding normally have high 




half-life in contrast to those with lower 
value. Large number of drugs bounded to 
plasma protein result into a small fraction of 
the drug being available for therapeutic 
effects, thereby reducing the quantity of 
drug in the blood circulation. Drugs bind to 
protein plasma such as human serum 
albumin, lipoprotein, glycoprotein, α, β‚ and 
γ globulins (Ntie-kang 2013). Herein, the 
plasma protein binding (PPB) was 
predicated by computing the predicated 
human serum albumin (log KHSA). The 
predicated log KHSA values (Table 3) suggest 
the compounds to bind to human serum 
albumin (HSA). The predicated PPB for all 
N-cinnamoyltetraketide derivatives were 
compared to the value in the literature as 
classified by discovery studio (Reddy et al. 
2012). The predicated value fell within level 
0. Though the compounds bind to plasma 
protein, the recorded value suggests that 
they can exert the intended therapeutic effect 
(Zhivkova  and Doytchinova 2012). 
 
Table 3: Predicated plasma protein binding properties of compounds t_1 – t_8 
 
Compounds log KHSA
a % PPBa Level  
t_1 3.37 89.05 0 
t-2 3.4 88.84 0 
t_3 3.67 89.65 0 
t_4 3.59 87.62 0 
t_5 3.64 86.73 0 
t_6 3.64 86.73 0 
t_7 3.53 70.87 0 
t_8 3.53 70.87 0 
a
Values were predicated by using ACD/Labs and compared to the value in the literature (Reddy et 
al. 2012) as classified by discovery studio 2.5 level 0 = PPB < 90 %, level 1 = PPB > 90 % and 
level 2 = PPB > 95 %. 
 
Predicting the inhibition of human ether-
a-go-go-related gene (hERG) channel  
The investigation on hERG channel 
inhibition is always needed in drug 
development in order to reduce expenses 
and cardiotoxicity, which may result when 
left unverified. The inhibition of the hERG 
channel results into drug-causing delay in 
ventricular repolarization [induce Q and T 
wave (QT) prolongation], which is a side 
effect of non-cardiovascular therapeutic 
agents (Aronov 2005, Song and Clarck 
2006). hERG is known to be associated with 
the modulation of some nervous system cell 
function (Aronov 2005), thus, hERG 
inhibitors are potentially toxic and need to 
be investigated earlier. In this study, hERG 
inhibition constant (Ki) was predicated to be 
<10 µM for all studied compounds (Table 
4). The blockage of hERG is known to 
decrease significantly for compounds having 
the calculated Clog P < 1. The limitation for 
potent hERG inhibitor is Clog P ≥ 3.7 
(Buyck 2002). N-cinnamoyltetraketide 
derivatives evaluated in this study had Clog 
P < 1 implying that they could be non-hERG 
blockers (Table 4). 
 
Predicted inhibition of the human 
cytochrome P450 enzymes (CYP) 2C19, 
2C9, 2D6, 3A4  
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Studying the inhibition potency of drug-like 
and lead-like molecules against cytochrome 
P450 (CYP) enzymes is crucial for 
determining their drug-drug interactions and 
drug toxicity. These enzymes are involved in 
biotransformation of drugs and xenobiotics. 
CYP 3A4 is known to metabolize almost 
half of the drugs used today (Reddy et al. 
2012). This enzyme is also concerned with 
oral bioavailability of drugs and hence the 
inhibition of such enzymes needs to be 
assessed earlier. In this study, the ability of 
compounds t_1 – t_8 to inhibit four human 
CYP 450 enzyme isoforms was predicated. 
It was found that all N-cinnamoyltetraketide 
derivatives under study were non-inhibitors 
to all four isoforms of human P450 enzymes 
(Table 5). According to the reported 
standard level of CYP 450 inhibitor (Reddy 
et al. 2012), all compounds were in level 0, 
which is the non-inhibition level.  
 
 








t_1 <10 0.02 Not reliable 
t_2 <10 0.02 Not reliable 
t_3 <10 0.10 Not reliable 
t_4 <10 0.09 Not reliable 
t_5 <10 0.02 Not reliable  
t_6 <10 0.02 Not reliable 
t_7 <10 0.01 Not reliable 
t_8 <10 0.01 Not reliable 
Table 5: Predicted inhibition of CYP450 enzymes by compounds t_1 – t_8  
 
Compounds 
Predicated Levels of Inhibition
a 
CYP 2C19 CYP 2C9 CYP 2D6 CYP 3A4 
t_1 0 0 0 0 
t-2 0 0 0 0 
t_3 0 0 0 0 
t_4 0 0 0 0 
t_5 0 0 0 0 
t_6 0 0 0 0 
t_7 0 0 0 0 
t_8 0 0 0 0 





Values were predicated in Pre ADMET online sever and results were compared to the standard 
value in the literature (Reddy et al. 2012) as classified in discovery studio 2.5, level 0 = non 
inhibitor, level 1= inhibitors. 
 
Bioavailability predications  
One among several reasons for drug failure 
in clinical application is their poor 
bioavailability. Therefore, oral 
bioavailability assessment should be done 
earlier during drug development. However, 
there are limited in vitro high throughput 
screening assays for oral bioavailability and 
hence other alternative approaches are 
necessary. Recently, in silico model to 
predict oral bioavailability has been 
developed (Ntie-Kang et al. 2013). In the 
present study, oral bioavailability of the N-
cynammoyltetraketide derivatives was 
carried out by in silico model for 
predictions. The predicated percentage 
fraction (% F) of the drug dose that reaches 
circulation after oral administration was 
studied by employing the number of 
endpoints that affect oral bioavailability 
which include solubility (dose/solubility 
ratio), stability in acidic media, intestinal 
membrane permeability (IMP) by passive or 
active transport, likelihood of P-gp efflux, 
first pass metabolism in the liver, Madin-
Darby canine kidney (MDCK) cell and 
colon carcinoma cell (Caco-2) permeability 
(Table 6). All compounds were predicted to 
possess good solubility and stability in 
acidic media as established at pH < 2. The 
compounds demonstrated also good 
absorption by passive transport. Compounds 
with more than 50% F are known to have 
high probability of oral bioavailability 
(Mandagere et al. 2002). Thus, the 
investigated compounds could be considered 
to have great chance of oral bioavailability. 
The predicated first pass metabolism (FPM) 
in the liver was in compliance except for 
compound t_5, t_6, t_7 and t_8. Similarly, 
P-gp efflux was predicated to be good for 
compounds t_1 and t_3, while the rest 
exhibited moderate response. On the other 
hand, all compounds showed poor intestinal 
membrane permeability (IMP) by active 
transport in contrast to passive transport. 
Furthermore, Madin-Darby canine kidney 
(MDCK) cell permeability, an important 
parameter mostly used to predict oral 
absorption was also predicated at a 
recommended range (<25 poor, >500 great) 
(Irvine et al. 1999). The results further ruled 
out the compounds to have poor absorption 
(Table 6). All compound were predicated to 
have moderate permeability to colon 
carcinoma cell (Caco-2 permeability), 
recording values within the recommended 
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Table 6: Predicated oral bioavailability of compounds t_1 – t_8 
 
Cpds 








active  eSolubility Stability 
(pH<2) MDCK Caco-2 
(OB)     
t_1 >70 Good Moderate Good Poor Good(3) Good 6.09 19.53 
t_2 >70 Moderate Moderate Good poor Good(3) Good 3.653 19.46 
t_3 >70 Good Moderate Good Poor  Good(3) Good 10.63 21.97 
t_4 >70 Moderate Good Good Poor Good(3) Good 17.93 20.64 
t_5 >70 Moderate  Problem Good Poor  Good(3) Good 17.1 18.94 
t_6 >70 Moderate  Problem Good Poor Good(3) Good 17.1 18.94 
t_7 >70 Moderate Problem  Good Poor Good(3) Good 4.59 18.17 
t_8 >70 Moderate Problem  Good poor Good(3) Good 4.59 18.17 
a
Percentage fraction of oral bioavailability of drug that reaches circulation after oral 
administration, 
b
Likelihood of P-gp efflux, 
c
First pass metabolism in the liver, 
d
Intestinal 
membrane permeability (absorption) by passive or active transport. 
e
predicated solubility, the level 
numbers in brackets are in accordance with the discovery studio classification for solubility as 
reported in literature (Reddy et al. 2012).  
 
Molecular docking studies on COX-2 
COX-2 enzyme was docked by the N-
cinnamoyltetraketide derivatives (t_1 - t_8) 
that were used as ligands to predict binding 
energy (inhibition) and interaction to the 
enzyme. Before docking was carried out, the 
protein was analyzed for its residues to 
establish whether they are in the allowed or 
disallowed regions. The Ramachadran plot 
(Figure 2a) shows that number of residues in 
the favoured region was 96 per cent and the 
number of residues in allowed region was 4 
per cent as expected. Further analyses of the 
protein with ProSA showed a good Z-score 
of -8.91 (Figure 2b) indicating quality of the 
protein. Z-score measures the deviation of 
total energy of the structure to an energy 
distribution obtained from random 
conformation. The energy diagram Figure 2c 
further indicated the quality of the protein 
with respect to its plotted knowledge-based 
energies against amino acid sequence. The 
docked compounds showed excellent 
binding pose energy to COX-2, with the best 
pose energy ranging between -6.5 and -13 
Kcal/mol (Table 7). Ligands t_3, t_4 and t_5 
showed low binding energy of -13, -9.2 and 
-12.3 kcal/mol, respectively, in comparison 
to other ligands. Since the binding energy is 
proportional to the inhibition constant, the 
obtained best pose binding energy implies 
that these molecules could potentially 
possess inhibition activities on COX-2 
enzyme. Lower binding energy indicates 
good compatibility with COX-2 protein 
receptor. When compared to a standard 
drug, celecoxib (Madeswaran et al. 2012, 
Adinarayana et al. 2012), ligands t_3 and t_5 
had the best pose energy close to that of 
celecoxib (-15.4 kcal/mol) (Table 7). 
Furthermore, the docking experiments were 
collated with the cytotoxic experimental 
values (Table 7, Figure 3) against the human 
breast cancer cells (Nyandoro et al. 2015). 
The experimental values correlated well 
with the docking experiments with r
2
 = The 
binding modes of ligands with best pose 
energy (t_3, t_4 and t_5) are presented in 




Figure 4. Ligand t_3 was found to bind to 
COX-2 with the binding pocket comprising 
of Asn1786, Glu1782, Arg1858, Tyr1789, 
Tyr1776, Lys1857, Phe1862, His1775, 
Gly1859, Val1774, Asp1799 and Glu2099 
amino acid residues. No hydrogen bonding 
was formed (Figure 4a). Docking of ligand 
t_4 indicated bounding to COX-2 pocket 
involves Phe526, Lys527, Asn530, Ile528, 
Phe331, Trp515 Glu523, Thr531, Lys312 
and Val524 residues. The ligand formed 
hydrogen bonding with Lys312 and Asn530 
amino acid residues (Figure 4b). The 
binding of ligand t_5 to COX-2 as viewed in 
Pymol indicated interaction with Asp1313, 
Gly522, Leu335, Ile523, Arg1314, Pro517 
and Lys330. Hydrogen bonding was formed 
between the ligand and amino acid residues 
Lys330 (Figure 4c). The observed hydrogen 
bonds and other interactions suggest 
possible targets of ligand t_5 to the COX-2 
enzyme that could lead to inhibition 
activities. Docking of celecoxib as a control 
drug interacted with amino acid residues 
Glu523, Gly522, Val524, Phe526, Lys527, 
Asn530, Thr531, Ile528 and Ile529. Amino 
acid residue Val524 formed hydrogen 
bonding with celecoxib. The X-ray structure 
of celecoxib complex (Figure 4d) was 
further compared with the docked ligand. It 
was observed that, the docked ligand bound 
in the same pocket as celecoxib bind (Figure 








Figure 2: (a) Ramachandran Plot analysis of 3NTG. The plot statistics are; number of residue in 
favoured regions 528 (96 %) and number of residue in allowed regions 22 (4 %), the 
number of residues in the disallowed region was o (0 %). (b) ProSA web service 
analysis of NTG. In ProSA web the Z-score is determined by X-ray crystallography 
(light blue) or NMR spectroscopy (dark blue) with respect to their length. The Z score 
of the protein is highlighted as large dot. (c) Energy plot of 3NTG obtained from the 
ProSA.  
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t_1 -7.2 105.7 -2.02 - - 
t_2 -8.2 NT    
t_3 -13 23.6 -1.37 - - 
t_4 -9.2 70.6 -1.86 2 Lys330, Asp332 
t_5 -12.3 15.5 -1.19 3 Lys512, Asn530 
t_6 -7.8 NT    
t_7 -6.5 NT    
t_8 -7.3 NT    
Celecoxib -15.4 - - 2 Val524, Gly522 
b
Experimental values as reported (Nyandoro et al. 2015), NT = not tested (experimentally) for 
breast cancer cell lines 
 
 















Figure 4: (a) Interaction of the amino acid residues of COX-2 enzyme with t_3 ligand as viewed 
by Molegro Molecular Viewer, (b) t_4 interacting with COX-2 amino acid residues as 
viewed in Pymol. Hydrogen bond was formed with Lys512 and Asn530 residues, 
hydrogen bonds are indicated by yellow dotted lines (c) Binding sites of t_5 to COX-2 
enzyme indicating the amino acid residues of COX-2 enzyme. Yellow dotted lines 
indicate hydrogen bonding, (d) X-ray crystal structure of celecoxib-COX-2 complex. 
Blue lines indicated hydrogen bond and grey line indicates hydrophobic interactions. 
Celecoxib is shown in orange color.  
 
Generally, the docking studies showed that 
the investigated ligands exhibit different 
binding orientations and to some extent, 
different or similar binding energies. 
Whereas ligand t_4 and t_5 were found to 
bind to similar pockets, ligand t_1 and t_3 
were bound to other pockets and oriented 
differently from t_4 and t_5. This may be 
explained by the fact that COX-2 possesses 
three pockets of active site notably 
hydrophilic and hydrophobic pockets, and a 
third pocket lined with His90, Arg513, and 
Val523 residues (Llorens et al. 2002). 
Docking of the N-cinnamoyltetraketide 
derivatives depicted different binding and 
orientation in COX-2 enzyme. The predicted 
binding and orientation of t_4 and t_5 were 
similar to celecoxib, a known COX-2 
inhibitor. However, compounds t_1 and t_3 
bound to a different pocket of the COX-2 
Tanz. J.Sci. Vol. 44(2) Spec. 2018 
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incompatible to celecoxib. The orientation 
of t_1 and t_3 in the pocket allowed their 
interactions to be closer to the amino acid 
residues Arg1858, Try1789, Asn1785 and 
Val524, Ile285, Glu523 Lys527, 
respectively. Docking analysis showed N-
cinnamoyltetraketide derivatives to possess 
different binding patterns, phenomena 
reported for other known synthetic Non-
Steroidal Anti-Inflammatory Drugs 
(NSAIDs) that are COX-2 inhibitors 
(Llorens et al 2002). Formation of H 
bonding for ligands t_4 and t_5 as for 
celecoxib suggests COX-2 inhibitory 
properties for these compounds. Though, 
ligand t_1 and t_3 did not indicate H-
bonding with any COX-2 amino acid 
residue, they showed a different mode of 
interaction with Val524, a residue found to 
interact with celecoxib. These results further 
suggest that N-cinnamoyltetraketide may 
inhibit COX-2 and therefore act as lead 




Pharmacokinetic profile and Lipinski Rule 
of Five evaluations of N-
cinnamoyltetraketide derivatives indicate 
potential drug or lead likeness. N-
cinnamoyltetraketide derivatives t_4 and t_5 
have shown a comparable binding pocket 
and interaction to the known COX-2 
inhibitor celecoxib in silico, unlike t_1 and 
t_3 that bound differently. The binding 
energy was in the order celecoxib (-15.4) > 
t_3 (-13) > t_5 (-12.3) > t_2 (-8.2) > t_6 (-
7.8) > t_8 (-7.3) > t_1 (-7.2) > t_7 (-6.7) 
further suggesting the compounds to possess 
inhibition properties, some being 
comparable to the standard drug. These in 
silico results serve as pilot information that 
could be extended to in vitro and in vivo 
studies for possible discovery of novel 
COX-2 inhibitors possessing different 
mechanistic pathways.  
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